| Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? JA Pinto, CS Vallejos, LE Raez, LA Mas, R Ruiz, JS Torres-Roman, ... ESMO open 3 (3), e000344, 2018 | 188 | 2018 |
| Entrectinib: a potent new TRK, ROS1, and ALK inhibitor C Rolfo, R Ruiz, E Giovannetti, I Gil-Bazo, A Russo, F Passiglia, ... Expert opinion on investigational drugs 24 (11), 1493-1500, 2015 | 168 | 2015 |
| Epidemiology and pathophysiology of pregnancy-associated breast cancer: a review R Ruiz, C Herrero, K Strasser-Weippl, D Touya, JS Louis, A Bukowski, ... The Breast 35, 136-141, 2017 | 142 | 2017 |
| End-of-life care in Latin America E Soto-Perez-de-Celis, Y Chavarri-Guerra, T Pastrana, R Ruiz-Mendoza, ... Journal of Global Oncology 3 (3), 261-270, 2017 | 83 | 2017 |
| Improving access to high‐cost cancer drugs in Latin America: much to be done R Ruiz, K Strasser‐Weippl, D Touya, C Herrero Vincent, ... Cancer 123 (8), 1313-1323, 2017 | 78 | 2017 |
| Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) A Ruiz‐Patiño, O Arrieta, AF Cardona, C Martín, LE Raez, ... Thoracic Cancer 11 (2), 353-361, 2020 | 64 | 2020 |
| Barriers in Latin America for the management of locally advanced breast cancer JA Pinto, L Pinillos, C Villarreal-Garza, Z Morante, MV Villarán, G Mejía, ... ecancermedicalscience 13, 897, 2019 | 60 | 2019 |
| Lung cancer in the young M Galvez-Nino, R Ruiz, JA Pinto, K Roque, R Mantilla, LE Raez, L Mas Lung 198 (1), 195-200, 2020 | 59 | 2020 |
| ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer G Rosas, R Ruiz, JM Araujo, JA Pinto, L Mas Critical reviews in oncology/hematology 136, 48-55, 2019 | 57 | 2019 |
| Immunotherapy in triple-negative breast cancer: A literature review and new advances GA Valencia, P Rioja, Z Morante, R Ruiz, H Fuentes, CA Castaneda, ... World Journal of Clinical Oncology 13 (3), 219, 2022 | 48 | 2022 |
| Entinostat (SNDX-275) for the treatment of non-small cell lung cancer R Ruiz, LE Raez, C Rolfo Expert opinion on investigational drugs 24 (8), 1101-1109, 2015 | 46 | 2015 |
| Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast cancer Z Morante, R Ruiz, JM Araujo, JA Pinto, G de la Cruz-Ku, ... Clinical Breast Cancer 21 (3), 239-246. e4, 2021 | 45 | 2021 |
| Clinical-pathological features and survival in young women with cervical cancer: A retrospective analysis from the instituto nacional de enfermedades neoplÁsicas R Ruiz, M Serrano, EF Ruiz, R Mantilla, N Valdivieso, M Olivera, ... Revista Peruana de Medicina Experimental y Salud Publica 34 (2), 218-227, 2017 | 42* | 2017 |
| Current and emerging therapies of HER2-positive metastatic breast cancer A Hernandez-Blanquisett, D Touya, K Strasser-Weippl, R Ruiz, JS Louis, ... The Breast 29, 170-177, 2016 | 38 | 2016 |
| Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines R Ruiz, B Hunis, LE Raez Current oncology reports 16 (9), 400, 2014 | 37 | 2014 |
| Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC L Lara-Mejía, AF Cardona, L Mas, C Martin, S Samtani, L Corrales, ... Journal of Thoracic Oncology 19 (1), 119-129, 2024 | 27 | 2024 |
| Potential new biomarkers for squamous carcinoma of the uterine cervix PA Van Dam, C Rolfo, R Ruiz, P Pauwels, C Van Berckelaer, XB Trinh, ... ESMO open 3 (4), e000352, 2018 | 27 | 2018 |
| Colorectal cancer in the young: clinicopathologic features and prognostic factors from a cancer institute in Peru R Ruiz, L Taxa, EF Ruiz, R Mantilla, L Casanova, P Montenegro Revista de Gastroenterología del Perú, 35-42, 2016 | 23* | 2016 |
| Update in immunotherapy for advanced non-small cell lung cancer: optimizing treatment sequencing and identifying the best choices K Roque, R Ruiz, L Mas, DH Pozza, M Vancini, JA Silva Júnior, ... Cancers 15 (18), 4547, 2023 | 20 | 2023 |
| Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key C Rabanal, R Ruiz, S Neciosup, H Gomez World journal of clinical oncology 8 (6), 437, 2017 | 19 | 2017 |
Henry GomezOncoSalud/AUNA (Lima, Peru)Verified email at gecoperu.org
